Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Pronase** is a heterogeneous broad-spectrum proteolytic enzyme preparation derived from extracellular enzymes of *Streptomyces griseus*. It contains multiple endopeptidases and exopeptidases that hydrolyze peptide bonds in proteins, including mucins within gastric and esophageal mucus. Clinically, oral pronase is used as a mucolytic premedication before upper gastrointestinal endoscopy to remove adherent mucus and improve visualization of the mucosal surface; it is an adjunct to diagnostic procedures rather than an anticancer treatment. The Japanese prescription product PRONASE MS is manufactured by Kaken Pharmaceutical and is administered as a powder dissolved in water, commonly with sodium bicarbonate, before gastroscopy. ([rad-ar.or.jp](https://www.rad-ar.or.jp/siori/english/search/result?n=35353))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pronase.